New CEOs at Axovant, Destiny and Organovo mark a busy week for the biotech jobs scene
Peer Review is the weekly biopharma jobs report from Endpoints News.
→ Musculoskeletal company Flexion Therapeutics $FLXN said co-founder Neil Bodick will transition to CSO from CMO. Yamo Deniz becomes CMO. Deniz was VP and global head of medical for rare diseases at the Genzyme unit of Sanofi.
→ Anti-infective firm Entasis Therapeutics named Mike Gutch CFO and CBO. He was executive director of corporate development at AstraZeneca.
→ Lorianne Masuoka joins Marinus Pharmaceuticals as their new CMO. She’s a neurologist who held chief medical roles at InVivo, Cubist, and Nektar previously.
→ Taylor Crouch is replacing Keith Murphy as CEO of San Diego-based Organovo $ONVO, a developer of human tissue models. Crouch was the CEO of eStudySite, and earlier in his career was senior vice president of marketing and sales at Parexel.
→ Oxford’s e-Therapeutics appointed Raymond Barlow as CEO. Barlow was previously executive director of corporate development at Amgen.
→ Destiny Pharma, an anti-microbial biotech, named Neil Clark as CEO. Bill Love, the previous CEO and scientific founder, is now the CSO.